OUR NEWS

Photograph: Ed Reschke / Getty Images

WIRED.com17 July 2023

A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It

THERE’S A MAJOR downside to semaglutide, the drug originally developed for diabetes and now prescribed for weight loss under the brand names Ozempic and Wegovy: People often stop...

BUSINESSWIRE.com26 June 2023

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita^® in Open Label Phase of Revitalize 1...

BUSINESSWIRE.com

Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+ Telehealth Program...

Press Releases

Jan 31, 2023

Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita^® DMR in Type 2 Diabetes

May 17, 2022

Fractyl Health to Present New Data on Revita^® DMR in Type 2 Diabetes at Digestive Disease Week 2022

Apr 4, 2022

Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

Feb 8, 2022

Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR^® System

Feb 1, 2022

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR^® Therapeutic Procedure in Patients with Type 2 Diabetes

Electronic Press Kit

In the News

Mar 10, 2023

New and Developing Diabetes Technologies Offer ‘Sweet Relief’

Mar 7, 2023

Longevity investment bulletin: Mitobridge, Fractyl, Insilico and more

Feb 13, 2023

Could an Intestinal Procedure Be the Future of Type 2 Diabetes Therapy?

Feb 8, 2023

Fractyl Health announces commercial availability of Revita duodenal mucosal resurfacing intervention for type 2 diabetes in Germany

Jan 31, 2023

Fractyl Health ‘encouraged’ by results from diabetes reversal study

Dec 5, 2022

Data backs gene therapy delivery system for treating type 2 diabetes from Fractyl Health

Oct 10, 2022

Fractyl Health Doubles Lab Space with 78K-SF Lease at GenLabs in Burlington

Jun 6, 2022

New treatment for diabetes patients

OUR NEWS

A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita® in Open Label Phase of Revitalize 1...

Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+ Telehealth Program...

News

Press Releases

In the News

You are now leaving the Fractyl.com website

YOU ARE ABOUT TO LEAVE A WEBSITE WHERE A MEDICAL DEVICE IS AVAILABLE FOR INVESTIGATIONAL USE UNDER THE OVERSIGHT OF THE UNITED STATES FOOD & DRUG ADMINISTRATION (FDA). THE PRODUCT IS INTENDED SOLELY FOR INVESTIGATIONAL PURPOSES AND HAS NOT YET RECEIVED FULL REGULATORY APPROVAL.

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita^® in Open Label Phase of Revitalize 1...